, Seyyedeh Mina Hejazian
, Kamal Boostani
, Alireza Mardomi
, Mohammadreza Ardalan* 1
Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
The incidence of chronic kidney diseases (CKDs) by rare etiologies is growing along with other CKDs. This mini-review discusses the epidemiology, pathogenesis, clinical presentation, and diagnosis of rare kidney disease recurrence after kidney transplantation (KTx) including primary hyperoxaluria (PH), adenine phosphoribosyl transferase (APRT), C3 glomerulopathy (C3 GP), and fibrillary glomerulonephritis (FGN). It was shown that PH, like acute rejection, causes delayed graft function, confusing the physicians. Moreover, C3 GP is more prevalent than FGN among kidney transplant patients. Therefore, it is necessary to monitor rare diseases (RDs) before KTx in patients with any history of bilateral nephrocalcinosis or nephrolithiasis.
Implication for health policy/practice/research/medical education:
Although kidney transplantation (KTx) is the standard gold therapy for end-stage renal disease (ESRD), this treatment is not a definitive and complete approach for kinds of rare chronic kidney disease (CKD) such as primary hyperoxaluria (PH), adenine phosphoribosyl transferase (APRT), C3 glomerulopathy (C3 GP), and fibrillary glomerulonephritis (FGN). These diseases frequently recur after kidney transplant, expect FGN mimic acute rejection. For this reason, monitoring of such rare diseases is necessary before KTx, especially in patients with any history of bilateral nephrocalcinosis or nephrolithiasis.
Please cite this paper as: Farnood F, Hejazian SM, Boostani K, Mardomi A, Ardalan M. Recurrence of rare disease after kidney transplant. J Nephropharmacol. 2023;12(1):e10519. DOI: 10.34172/npj.2022.10519.